Petrelintide Phase 3: Roche and Zealand Push Pure Amylin Analog as Gentler GLP-1 Alternative

Important Notice: This article is intended exclusively for scientific information and research purposes. All substances mentioned are not intended for human consumption. Always consult qualified professionals before using peptides.

Introduction: A New Chapter for Amylin

On 29 April 2026, Roche and Zealand Pharma jointly announced that petrelintide (ZP8396), a long-acting pure amylin analog without any GLP-1 component, will advance into Phase 3 trials. The pivotal program, named ZUPREME-1, is scheduled to begin in the second half of 2026 and targets chronic weight management in adults with overweight or obesity.

The announcement is more than a routine pipeline update. It represents the first time a pure amylin analog – with no GLP-1, no GIP, and no glucagon agonism – enters Phase 3 for chronic weight management since cagrilintide. After CagriSema reportedly missed its 25% weight-loss target last year, both partners are now openly positioning petrelintide as a leaner, gentler alternative to GLP-1 monotherapy and to combination products like CagriSema.

For researchers fatigued by GLP-1 gastrointestinal profiles and looking at next-generation mechanisms, the amylin-only path is suddenly back at the centre of the obesity conversation.

What Is Petrelintide? Pharmacology of a Pure Amylin Analog

Petrelintide is a long-acting peptide analog of human amylin, a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. Like cagrilintide, petrelintide is engineered for once-weekly subcutaneous dosing, but it is a structurally distinct molecule developed by Zealand Pharma and now globally co-developed with Roche.

Mechanism of action

Activates calcitonin and amylin receptors in the area postrema and hindbrain
Slows gastric emptying, prolonging postprandial satiety
Suppresses postprandial glucagon release
Reduces food intake through central nervous system pathways distinct from GLP-1

Differences vs. cagrilintide

Cagrilintide was developed as a partner peptide for semaglutide inside the CagriSema combination. Petrelintide, by contrast, is being developed as a stand-alone monotherapy. Reported preliminary Phase 2 data suggest weight loss in the order of approximately 8.6% at the higher dose over the trial period, with a gastrointestinal tolerability profile that the sponsors describe as milder than typical GLP-1 mono therapies.

Because amylin physiology centres on gastric emptying and hindbrain satiety rather than on hypothalamic appetite suppression and pancreatic GLP-1 signalling, the side-effect signature differs in kind, not only in degree, from incretin-based therapies.

How It Differs From GLP-1 and CagriSema

The clearest way to position petrelintide is alongside the dominant incretin-based products and the current amylin-containing combination, CagriSema.

Parameter	Semaglutide 2.4 mg	Tirzepatide 15 mg	CagriSema	Petrelintide
Mechanism	GLP-1	GLP-1 + GIP	GLP-1 + Amylin	Amylin only
Cadence	Once weekly s.c.	Once weekly s.c.	Once weekly s.c.	Once weekly s.c.
Reported weight loss	~14.9% (Phase 3)	~22.5% (Phase 3)	22.7% (Phase 3)	~8.6% (preliminary Phase 2)
GI tolerability	Moderate, dose-limiting in many	Moderate	Moderate, similar to GLP-1	Reportedly milder
Approval status	Approved (Wegovy)	Approved (Zepbound)	FDA NDA 12/2025	Phase 3 (ZUPREME-1, H2 2026)

Petrelintide does not aim to beat retatrutide or tirzepatide on raw percentage weight loss. Instead, it targets a different value proposition: a single, simpler hormonal axis with a more tolerable profile, potentially appealing to patients who cannot tolerate GLP-1 mono- or combination therapies.

ZUPREME-1 Trial Design: What We Know So Far

According to the 29 April 2026 announcement, ZUPREME-1 is the first of a planned global Phase 3 program for petrelintide in chronic weight management. The headline points disclosed so far:

Indication: chronic weight management in adults with overweight or obesity
Programme name: ZUPREME-1 (further trials expected to follow)
Start: second half of 2026
Sponsor structure: joint development by Roche and Zealand Pharma
Format: long-acting once-weekly subcutaneous injection

Detailed protocol parameters – sample size, primary endpoint duration, comparator arms, and specific dose levels – will be communicated by the sponsors when the programme is registered. Researchers should monitor clinicaltrials.gov entries linked to ZP8396 once filings appear.

What is already clear is the strategic intent: by running a dedicated monotherapy Phase 3 rather than only pursuing combinations, Roche and Zealand are positioning amylin as a stand-alone class, not merely a partner peptide for GLP-1 agonists.

Why Pure Amylin Is Interesting Right Now

The timing of the petrelintide Phase 3 announcement is not accidental. Three converging trends explain why the pure-amylin thesis is gaining ground in 2026.

1. The GLP-1 tolerability ceiling

Real-world persistence data on semaglutide and tirzepatide consistently show meaningful drop-off due to nausea, vomiting and other gastrointestinal effects, particularly at higher doses. Even where weight loss is impressive on paper, a substantial proportion of patients discontinue within the first year. A peptide with a milder GI profile has a clear commercial and clinical opening.

2. The CagriSema 25% miss

CagriSema delivered an impressive 22.7% weight loss in REDEFINE 1 with full adherence, but reportedly missed Novo Nordisk's internal 25% target. That has shifted the strategic question away from "how high can we push absolute weight loss?" toward "how can we deliver durable, tolerable weight loss in real-world use?" Pure amylin is positioned as a candidate answer.

3. Mechanistic differentiation in a crowded field

With semaglutide, tirzepatide, retatrutide, CagriSema, oral GLP-1s and survodutide all in or near the market, mechanistic differentiation matters. A pure amylin analog is the clearest non-GLP-1 obesity story available. It also opens a path to future combinations on the partner side, including with Roche's own pipeline assets.

Significance for the EU Research Context

Petrelintide is currently not commercially available; outside of clinical trials the compound does not exist on the market. For preclinical and in vitro research, individual amylin and amylin-analog reference materials are available, and combinatorial protocols with established GLP-1 reference peptides can be examined in suitable research settings to characterise the amylin axis.

Researchers tracking the obesity pipeline in 2026 should view petrelintide not as a direct successor to retatrutide, but as a structurally different bet on the question: which weight-loss therapy will patients actually stay on for five years?

Conclusion: The Quiet Bet on Tolerability

The 29 April 2026 Roche and Zealand announcement marks the return of pure amylin to the centre of metabolic medicine. After more than a decade in which obesity research was effectively defined by incretin biology, a major pharmaceutical alliance is now publicly betting that the next leg of growth will come from a different mechanism entirely.

Key takeaways:

Petrelintide (ZP8396) advances to Phase 3 ZUPREME-1, starting H2 2026
First post-cagrilintide pure-amylin Phase 3 in chronic weight management
Preliminary Phase 2 weight loss reported at approximately 8.6% at the higher dose
Positioned as a leaner, gentler alternative to GLP-1 mono and CagriSema combo
Joint global development by Roche and Zealand Pharma

Open questions:

Final ZUPREME-1 protocol details and primary endpoint
Head-to-head data versus semaglutide, tirzepatide and CagriSema
Long-term durability of weight loss and discontinuation profile
Future combination strategies inside the Roche pipeline

For GLP-1-fatigued researchers, petrelintide is the most interesting non-incretin obesity story of 2026. The wager is no longer just on bigger numbers, but on a therapy patients can plausibly stay on.

Sources

BioSpace. "Zealand Pharma and Roche to Advance Petrelintide, an Amylin Analog, to Phase 3 Trials for Chronic Weight Management." Press release, 29 April 2026.
Zealand Pharma corporate communications, ZP8396 development programme.
Garvey WT, et al. "Cagrilintide-Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)." New England Journal of Medicine. DOI: 10.1056/NEJMoa2502081.
Novo Nordisk. "Novo Nordisk files for FDA approval of CagriSema." PR Newswire, 18 December 2025.